{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:18:19Z","timestamp":1790957899390,"version":"4.1.0"},"reference-count":9,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,20]],"date-time":"2021-03-20T00:00:00Z","timestamp":1616198400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadcasereports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD Case Reports"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.jdcr.2021.03.028","type":"journal-article","created":{"date-parts":[[2021,3,27]],"date-time":"2021-03-27T12:33:31Z","timestamp":1616848411000},"page":"99-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Repigmentation in a patient with vitiligo on crisaborole 2% ointment"],"prefix":"10.1016","volume":"11","author":[{"given":"Idy","family":"Tam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared S.","family":"Kahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jdcr.2021.03.028_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13555-013-0023-0","article-title":"Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases","volume":"3","author":"Wittmann","year":"2013","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"10.1016\/j.jdcr.2021.03.028_bib2","doi-asserted-by":"crossref","first-page":"e12923","DOI":"10.1111\/dth.12923","article-title":"Apremilast is effective in controlling the progression of adult vitiligo: a case series","volume":"32","author":"Majid","year":"2019","journal-title":"Dermatol Ther"},{"key":"10.1016\/j.jdcr.2021.03.028_bib3","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","article-title":"Phosphodiesterase-4 inhibitors for the treatment of inflammatory diseases","volume":"9","author":"Li","year":"2018","journal-title":"Front Pharmacol"},{"issue":"4","key":"10.1016\/j.jdcr.2021.03.028_bib4","doi-asserted-by":"crossref","first-page":"e18907","DOI":"10.1371\/journal.pone.0018907","article-title":"Th17 cells and activated dendritic cells are increased in vitiligo lesions","volume":"6","author":"Wang","year":"2011","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.jdcr.2021.03.028_bib5","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jid.2016.09.016","article-title":"Keratinocyte-derived chemokines orchestrate T-cell positioning in the epidermis during vitiligo and may serve as biomarkers of disease","volume":"137","author":"Richmond","year":"2017","journal-title":"J Invest Dermatol"},{"issue":"2","key":"10.1016\/j.jdcr.2021.03.028_bib6","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jdcr.2021.03.028_bib7","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.jdcr.2021.03.028_bib8","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.jid.2019.11.031","article-title":"Apremilast in combination with narrowband UVB in the treatment of vitiligo: a 52-week monocentric prospective randomized placebo-controlled study","volume":"140","author":"Khemis","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jdcr.2021.03.028_bib9","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/pde.14443","article-title":"Low dose oral corticosteroids, microneedling, and topical 5-fluorouracil: a novel treatment for recalcitrant pediatric vitiligo","volume":"38","author":"Marasca","year":"2021","journal-title":"Pediatr Dermatol"}],"container-title":["JAAD Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621002058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352512621002058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:23:01Z","timestamp":1762474981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352512621002058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":9,"alternative-id":["S2352512621002058"],"URL":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.03.028","relation":{},"ISSN":["2352-5126"],"issn-type":[{"value":"2352-5126","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repigmentation in a patient with vitiligo on crisaborole 2% ointment","name":"articletitle","label":"Article Title"},{"value":"JAAD Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdcr.2021.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier, Inc.","name":"copyright","label":"Copyright"}]}}